MRVI Stock Cash Flow Statements

Maravai LifeSciences Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Maravai LifeSciences Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-06-30	2021-03-31

operating activities:
net income	-69,837,000	-52,853,000	-46,495,000	-175,955,000	-14,492,000	-22,680,000	-109,982,000	-15,102,000	-11,943,000	-1,348,000	87,429,000	99,653,000	156,721,000	146,860,000	126,244,000	210,196,000	75,852,000
adjustments to reconcile net income to net cash from operating activities:
depreciation	5,957,000	5,693,000	5,466,000	5,044,000	5,556,000	4,786,000	3,932,000	4,071,000	2,815,000	2,080,000	1,962,000	1,857,000	1,892,000	1,855,000	-210,000	4,151,000	1,854,000
amortization of intangible assets	7,200,000	7,030,000	6,902,000	6,891,000	6,869,000	6,869,000	6,869,000	6,870,000	6,852,000	6,765,000	6,236,000	6,254,000	6,252,000	5,527,000	3,654,000	10,081,000	5,040,000
amortization of operating lease right-of-use assets	2,229,000	2,187,000	2,158,000	2,104,000	2,122,000	2,098,000	2,179,000	2,155,000
amortization of deferred financing costs	391,000	461,000	658,000	754,000	744,000	740,000	743,000	738,000	729,000	719,000	654,000	724,000	711,000	699,000	681,000	1,319,000	654,000
stock-based compensation expense	6,789,000	10,403,000	10,545,000	13,050,000	13,763,000	12,057,000		9,987,000	9,272,000	5,987,000		4,740,000
change in estimated fair value of contingent consideration			-630,000	-178,000			-3,355,000	2,385,000			0	0
goodwill impairment	30,449,000	12,435,000	11,912,000
acquisition related tax adjustment
change in fair value of derivative instruments						-1,919,000
other	1,193,000	-236,000	-645,000	1,349,000	-94,000	223,000	2,161,000	-985,000	-4,041,000	552,000	-2,464,000	-4,246,000	-298,000	-985,000	594,000	-389,000	-144,000
changes in operating assets and liabilities, net of acquisitions:
accounts receivable	501,000	10,160,000	-11,345,000	9,842,000	-2,021,000	17,883,000	-8,785,000	3,212,000	7,561,000	82,407,000	-25,774,000	5,834,000	-115,000	-2,217,000	-51,540,000	-36,471,000	-70,812,000
inventory	3,108,000	449,000	327,000	-1,521,000	751,000	820,000	-2,184,000	-1,495,000	7,711,000	-3,383,000	19,273,000	-2,312,000	-8,703,000	1,201,000	4,689,000	-18,073,000	-13,828,000
prepaid expenses and other current assets	-2,862,000	2,241,000
accounts payable	1,782,000	-708,000	2,254,000	-2,420,000	4,571,000	-3,682,000	1,659,000	1,986,000	1,874,000	-235,000	-3,468,000	-4,420,000	4,360,000	1,950,000	-867,000	4,085,000	1,897,000
accrued expenses and other current liabilities	5,917,000	1,457,000	-1,636,000	1,000	2,997,000	-24,116,000	6,146,000	2,380,000	-17,643,000	24,225,000	-5,611,000	15,887,000	2,289,000	-4,062,000	6,619,000	-13,916,000	-11,044,000
deferred revenue	-1,116,000	381,000	540,000	-244,000	-132,000	-1,150,000	808,000	94,000	406,000	-1,058,000	-2,735,000	388,000	1,742,000	-6,518,000	-56,505,000	31,430,000	41,114,000
other long-term liabilities	-6,188,000	-8,490,000	-1,150,000	-298,000	-3,725,000	-1,126,000	-1,640,000	-1,084,000	-2,651,000	-10,603,000	2,079,000	991,000	1,868,000	-1,109,000	-4,788,000	-1,000	-280,000
net cash from operating activities	-10,265,000	-9,390,000	-14,638,000	13,136,000	17,434,000	-8,467,000	7,790,000	14,166,000	19,194,000	85,074,000	99,335,000	110,059,000	164,279,000	162,304,000	58,167,000	204,547,000	38,715,000
capex	-2,874,000	-5,235,000	-5,849,000	-8,591,000	-9,553,000	-5,665,000	-16,799,000	-15,827,000	-25,059,000	-7,868,000	-6,214,000	-6,467,000	-1,661,000	-2,748,000	-5,662,000	-7,782,000	-3,580,000
free cash flows	-13,139,000	-14,625,000	-20,487,000	4,545,000	7,881,000	-14,132,000	-9,009,000	-1,661,000	-5,865,000	77,206,000	93,121,000	103,592,000	162,618,000	159,556,000	52,505,000	196,765,000	35,135,000
investing activities:
cash paid for acquisitions of a business, net of cash acquired	-362,000	-18,628,000
purchases of property and equipment	-2,874,000	-5,235,000	-5,849,000	-8,591,000	-9,553,000	-5,665,000	-16,799,000	-15,827,000	-25,059,000	-7,868,000	-6,214,000	-6,467,000	-1,661,000	-2,748,000	-5,662,000	-7,782,000	-3,580,000
proceeds from government assistance allocated to property and equipment	0	734,000	1,718,000	632,000	3,371,000	1,421,000	3,896,000	307,000	634,000	8,028,000
net cash from investing activities	-3,236,000	-23,129,000	-4,931,000	-8,959,000	-6,182,000	-4,244,000	-12,903,000	-15,520,000	-24,157,000	-69,730,000	-18,520,000	-5,847,000	-1,661,000	-241,584,000	-5,662,000	-7,234,000	-3,032,000
financing activities:
distributions for tax liabilities to non-controlling interest holder				0
principal repayments of long-term debt	-1,360,000	-1,360,000	-230,313,000	-1,360,000	-1,360,000	-1,360,000	-1,360,000	-1,360,000	-1,360,000	-1,360,000	-1,360,000	-1,360,000	-1,360,000	-9,815,000	-1,500,000	-3,000,000	-1,500,000
payments of finance lease liabilities	-187,000	-183,000	-180,000	-160,000	-148,000	-145,000	-142,000	-124,000
proceeds from interest rate cap agreement	0	1,375,000	2,225,000
taxes paid for shares withheld under employee equity plans, net of proceeds from issuance of class a common stock	13,000	-4,732,000			-28,000	-1,433,000
net cash from financing activities	-1,534,000	-4,900,000	-236,189,000	809,000	228,000	-560,000	470,000	783,000	-43,134,000	-19,209,000	-66,123,000	-37,442,000	-43,411,000	-40,523,000	-48,998,000	-58,550,000	-24,199,000
effects of exchange rate changes on cash and cash equivalents	-111,000	73,000
net decrease in cash and cash equivalents	-15,146,000	-37,346,000			11,480,000	-13,271,000
cash and cash equivalents, beginning of period	0	322,399,000	0	0	0	574,962,000	0	0
cash and cash equivalents, end of period	-15,146,000	285,053,000	-255,758,000	4,986,000	11,480,000	561,691,000
supplemental cash flow information:
cash paid for interest	6,119,000	6,518,000				12,140,000				9,593,000	8,782,000	5,284,000	4,759,000	1,373,000	4,204,000	15,547,000	7,947,000
cash paid for income taxes		139,000									3,451,000	5,725,000	12,942,000	914,000	5,904,000	9,087,000	2,725,000
loss on extinguishment of debt											0	0	0	208,000
deferred income taxes							764,750,000	-5,532,000	-2,756,000	-1,520,000	7,011,000	9,234,000	12,856,000	13,217,000	17,466,000	18,211,000	11,760,000
revaluation of liabilities under the tax receivable agreement			1,000				-671,228,000	1,007,000	-101,000	1,436,000	6,442,000	0	0	-2,340,000
prepaid expenses and other current and noncurrent assets			996,000
cash paid for acquisition, net of cash acquired
acquisition deposit
prepaid lease payments on finance lease yet to commence										-159,000
purchase of technology			-500,000
proceeds from sale of business, net of cash divested											0				0
distributions to non-controlling interests holders
proceeds from borrowings of long-term debt, net of discount
financing costs paid to acquire long-term debt
payment of acquisition consideration holdback							0	0	0	-9,706,000
payments to mlsh 1 pursuant to the tax receivable agreement							0	0
payments to mlsh 2 pursuant to the tax receivable agreement							0	0
(taxes paid for shares withheld) proceeds from issuance of class a common stock under employee equity plans			-602,000
net increase in cash and cash equivalents			-255,758,000				-4,643,000
cash paid (refunded) for income taxes
supplemental disclosures of non-cash activities:
property and equipment included in accounts payable and accrued expenses										1,175,000	-98,000	-346,000	403,000	1,742,000	1,323,000	1,360,000	1,415,000
accrued receivable for capital expenditures to be reimbursed under a government contract										616,000
right-of-use assets obtained in exchange for finance lease liabilities
right-of-use assets obtained in exchange for operating lease liabilities
fair value of contingent consideration liability recorded in connection with acquisition of a business										5,289,000	0	0
accrued consideration payable for mychem acquisition
cash paid for acquisition of a business, net of cash acquired								0	109,000	-69,731,000		0	0	-238,836,000
changes in operating assets and liabilities:
prepaid expenses and other assets					-199,000	730,000	6,375,000	3,479,000	21,294,000	-23,012,000	-16,498,000	-26,323,000	-12,569,000	2,517,000	-1,923,000	-5,013,000	98,000
proceeds from derivative instruments					2,336,000	2,378,000	2,323,000	1,955,000	1,398,000	492,000
distributions for tax liabilities to non-controlling interest holders								0
equity-based compensation expense														3,627,000	2,230,000	4,661,000	2,278,000
gain on sale of business															0
government funding receivable
proceeds from sale of building															0	548,000	548,000
shares withheld for employee taxes, net of proceeds from issuance of class a common stock under employee equity plans										-333,000
effects of exchange rate changes on cash															-133,000	13,000	7,000
cash (refunded) paid for income taxes
right-of-use assets obtained in exchange for new finance lease liabilities
right-of-use assets obtained in exchange for new operating lease liabilities										3,931,000	9,641,000	7,099,000	0	773,000
recognition of deferred tax assets as a result of exchanges of llc units and cash contribution
recognition of liabilities under the tax receivable agreement
proceeds from borrowings of long-term debt												0	0	8,455,000
proceeds from issuance of class a common stock under employee equity plans, net of shares withheld for employee taxes								312,000
amortization of right-of-use assets										2,062,000	1,831,000	1,798,000
distributions for tax liabilities to non-controlling interests holders										-8,302,000		-36,812,000	-42,588,000	-39,889,000		-56,203,000	-23,128,000
net decrease in cash										-3,865,000
cash, beginning of period										632,138,000	0	0	0	551,272,000	0	236,184,000	236,184,000
cash, end of period										628,273,000	14,692,000	66,770,000	119,207,000	431,469,000	3,374,000	374,710,000	247,675,000
cash (received) paid for income taxes										-521,000
property and equipment obtained in exchange for finance lease obligations										17,067,000
prepaid lease payments on finance lease yet to commence included in accounts payable and accrued expenses										20,552,000
gain on sale and leaseback transaction
acquired and in-process research and development costs
financing costs incurred for line of credit
financing costs incurred for long-term debt
repurchase of incentive units
payment of contingent consideration
payments made on facility financing lease obligation and capital lease																-365,000	-141,000
payment for non-controlling interests in mlsc
payment to mlsh 2 for blocker mergers
proceeds from issuance of class a common stock sold in ipo, net of offering costs
proceeds from issuance of class b common stock sold to mlsh 1
purchase of llc units from mlsh 1
repurchase of class a common stock from mlsh 2
net increase in cash											14,692,000	66,770,000	119,207,000	-119,803,000	3,374,000	138,526,000
financing cost deducted from long-term debt proceeds
building and improvements capitalized under lease financing transaction
exchange of units for mlsc non-controlling interests
exchange of class a common stock for the blocker mergers
recognition of deferred tax assets from organizational transactions, subsequent exchanges and cash contribution
ipo issuance costs included in accounts payable and accrued expenses
receivable from lessor funded financing
proceeds from employee stock purchase plan and exercise of stock options, net of shares withheld for employee taxes												730,000	537,000	726,000
accrued consideration payable												0	0	10,000,000
recognition of deferred tax assets as a result of exchange of llc units																156,647,000
net increase in cash including cash classified within current assets held for sale																138,776,000
less: net increase in cash classified within current assets held for sale																-250,000
supplemental disclosures of non-cash investing and financing activities:
non-cash operating lease expense														1,874,000
fair value of contingent consideration liability recorded in connection with acquisition of business in other long-term liabilities														7,800,000
operating activities
loss on long-term debt refinancing
revaluation of liabilities payable to related parties pursuant to a tax receivable agreement
investing activities
cash paid for asset acquisition, net of cash acquired
financing activities
supplemental cash flow information
supplemental disclosures of non-cash investing and financing activities
building and improvements capitalized under lease financing transactions
property and equipment under new capital lease
revaluation of liabilities under tax receivable agreement																-5,886,000	-5,886,000
proceeds from employee stock purchase plan																1,018,000	570,000
recognition of liabilities under tax receivable agreement																137,706,000
deferred financing costs included in accounts payable and accrued expenses
repurchase liability for incentive units
repurchase liability for noncontrolling interests
non-cash interest expense recognized on lease facility financing obligation																162,000	162,000
north america																65,715,000
europe, the middle east and africa																106,046,000
asia pacific																20,760,000
latin and central america
total revenue																192,521,000
net increase in cash, and restricted cash																	11,491,000
for the three months ended march 31, 2021
change in benefit from doubtful accounts
other assets
earn-out liability
working capital adjustment for acquisition in prior year
acquisition of patents
recognition of deferred tax assets from organizational transactions

We provide you with 20 years of cash flow statements for Maravai LifeSciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Maravai LifeSciences stock. Explore the full financial landscape of Maravai LifeSciences stock with our expertly curated income statements.

The information provided in this report about Maravai LifeSciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.